VRDN-003
VRDN-003-303
Phase 3 small_molecule active
Quick answer
VRDN-003 for Thyroid Eye Disease (TED) is a Phase 3 program (small_molecule) at Viridian Therapeutics, Inc.\DE with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Viridian Therapeutics, Inc.\DE
- Indication
- Thyroid Eye Disease (TED)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active